Lista de obras -

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

artículo científico publicado en 2010

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia ⬇️

artículo científico publicado el 1 de agosto de 2011

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia ⬇️

artículo científico publicado el 28 de marzo de 2012

An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate ⬇️

artículo científico publicado el 4 de septiembre de 2012

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

artículo científico publicado en 2011

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

artículo científico publicado en 2011

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.

artículo científico publicado en 2019

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

artículo científico publicado en 2020

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data

artículo científico publicado en 2011

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia

artículo científico publicado en 2020

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

scientific article published on 01 November 2019

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

article by Adam J Savitz et al published 2019 in Neuropsychiatric Disease and Treatment

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

artículo científico publicado en 2020

Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference

artículo científico publicado en 2003

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia ⬇️

artículo científico publicado el 8 de marzo de 2011

Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

artículo científico publicado en 2016

Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

artículo científico publicado en 2020

Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention

artículo científico publicado en 2010

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

artículo científico publicado en 2010

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

scientific article published on 25 October 2018

Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia ⬇️

artículo científico publicado el 23 de marzo de 2012

Lista de obras de

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia ⬇️

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia ⬇️

An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate ⬇️

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia ⬇️

Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia ⬇️